Embecta vs Teleflex
EMBC and TFX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EMBC and TFX compare
Teleflex is the larger company, worth 19 times as much as Embecta ($6.8B against $348M).
Teleflex grew revenue faster over the last twelve months (30.7% versus −7.6% for Embecta).
Embecta keeps more of each dollar of sales as profit, with a net margin of 8.6% compared with −45.8% at Teleflex.
Both pay dividends: Embecta yields 5.2% and Teleflex 0.64%.
Embecta scores higher on the StockData Score (15 against 7 for Teleflex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EMBC | TFX |
|---|---|---|
| Size and price | ||
| Market cap | $348M | $6.8B |
| Share price | $6.15 | $159.55 |
| Change, 1 year | −57.7% | 49.1% |
| Change, 5 years | – | −47.7% |
| Beta (5Y) | 0.22 | 0.35 |
| Employees | 1,850 | 16K |
| StockData Score | ||
| Total score | 15 (better) | 7 |
| Valuation score | 6 (better) | 1 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 1 | 1 |
| Dividend score | 5 (better) | 3 |
| Valuation | ||
| P/E | 4.2× | – |
| P/S | 0.3× (better) | 3.0× |
| P/B | – | 2.3× |
| EV/EBITDA | 5.9× (better) | 48.1× |
| P/FCF | 2.1× (better) | 40.1× |
| FCF yield | 47.2% (better) | 2.5% |
| Fair value | $30.75 | $37.56 |
| Margin of safety | 80.0% (better) | −325% |
| Growth | ||
| Revenue growth (TTM) | −7.6% | 30.7% (better) |
| Revenue growth, 5Y average | −0.09% (better) | −4.7% |
| Net income growth (TTM) | 4.7% (better) | −638% |
| EPS growth (TTM) | 2.8% (better) | −645% |
| EPS growth, 5Y average | −26.4% | – |
| Profitability | ||
| Gross margin | 59.0% (better) | 54.9% |
| Operating margin | 21.9% (better) | 2.0% |
| Net margin | 8.6% (better) | −45.8% |
| FCF margin | 16.2% (better) | 7.5% |
| Return on equity | – | −28.9% |
| Return on invested capital | 26.2% (better) | 0.62% |
| Financial health | ||
| Debt / equity | – | 0.97 |
| Net debt / EBITDA | 4.63 (better) | 13.01 |
| Interest coverage | – | 0.4× |
| Current ratio | 1.68 | 2.60 (better) |
| Altman Z-score | 1.32 | 1.60 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | 5.2% (better) | 0.64% |
| Payout ratio | 31.1% | – |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | – | 3.7% |
| Shareholder yield | 5.2% (better) | 4.3% |
| Ownership | ||
| Held by institutions | 88.9% | 113% |
| Held by insiders | 3.9% | 0.73% |
| Insider net buying, 12 months | $521K | – |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 10.7% | 9.7% |
Go deeper
- EMBC stock overview
- EMBC income statement
- EMBC valuation and score
- TFX stock overview
- TFX income statement
- TFX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.